| Primary Cognitrax memory score | After 24 weeks, no advantage of the extract mixture over placebo was found for the primary memory score.Memory composite: change +16.2±20.9 versus +11.1±18.5; difference in raw changes +5.1 points, no statistically significant between-group difference for the primary outcome | 2/4 LowPrecision of the estimate: 40 participants, CI of the primary contrast not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow study question. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Manufacturer links and many secondary outcomes. | 11 randomised trialEffects of Curcuma longa extract on cognitive function in healthy participants with subtle cognitive weaknesses within the normal range: a randomized, double-blind, placebo-controlled trial ↗ | 40 healthy Japanese adults aged 40–69 with relatively low memory scores, 20 versus 20 | - Effects of Curcuma longa extract on cognitive function in healthy participants with subtle cognitive weaknesses within the normal range: a randomized, double-blind, placebo-controlled trial ↗
|
|---|
| instrument-measured spot intensity | After 60 days, instrument-measured spot intensity fell by 2.28% with WDTE60N versus 0.31% with placebo in the 90 women who completed the study.Decrease in instrument-measured spot intensity from baseline: 2.28% versus 0.31% by day 60 | 1/4 Very lowPrecision of the estimate: CI of the contrast not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: One instrument-measured outcome for a specific product. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Attrition, manufacturer and multiple outcomes. | 11 randomised trial (96 randomised, 90 completed; both skin measures in one trial)Efficacy and Safety of an Oral Low-Dose Water-Dispersible Turmeric Extract Capsule on Facial Skin Health in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 96 healthy women aged 18–40 with facial spots, 45 and 45 completed | - Efficacy and Safety of an Oral Low-Dose Water-Dispersible Turmeric Extract Capsule on Facial Skin Health in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| hydration by MoistureMeterSC | After 60 days, the instrument-measured hydration value changed from 19.31 to 24.47 with WDTE60N and from 19.46 to 17.27 with placebo in the 90 women who completed the study.19.31±9.86→24.47±8.97 versus 19.46±12.39→17.27±9.94 arbitrary units; raw difference in changes +7.35, p=0.001 according to the authors. | 1/4 Very lowPrecision of the estimate: 90 completed, CI of the contrast absent. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Instrument-measured outcome in women with facial spots. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Completer analysis, several measures and manufacturer links. | 11 randomised trial (96 randomised, 90 completed; both skin measures in one trial)Efficacy and Safety of an Oral Low-Dose Water-Dispersible Turmeric Extract Capsule on Facial Skin Health in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | 96 healthy women aged 18–40 with a facial spot, 45 and 45 completed | - Efficacy and Safety of an Oral Low-Dose Water-Dispersible Turmeric Extract Capsule on Facial Skin Health in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| Knee pain in osteoarthritis: WDTE60N | Knee pain decreased more with WDTE60N than with placebo over 90 days: an additional reduction of about 8.39 mm on a 0–100 mm scale.mean reduction 14.41 versus 6.02 mm, difference in changes about −8.39 mm; p<0.0001; group CIs are not CIs of the difference | 2/4 LowPrecision of the estimate: Exact CI of the difference not reported, magnitude small relative to the scale. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Completer analysis, manufacturer funding. | 11 randomised trialEfficacy and Safety of a Novel Low-Dose Water-Dispersible Turmeric Extract in the Management of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗ | 140 randomised adults with knee osteoarthritis, 139 completed: 70 and 69 | - Efficacy and Safety of a Novel Low-Dose Water-Dispersible Turmeric Extract in the Management of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗
|
|---|
| Pain after walking in chronic knee pain without arthritis | In adults with chronic knee pain without radiographic arthritis, pain after brisk walking fell by about 0.9 points out of 10 more with WDTE60N than with placebo.change −1.5±0.7 versus −0.6±0.8 points out of 10, p<0.0001; approximate difference −0.9 points | 2/4 LowPrecision of the estimate: Exact CI of the difference absent. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: 10 of 106 dropped out, sponsored study. | 11 randomised trialA Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with Chronic Knee Pain ↗ | 106 adults aged 18–60 with chronic knee pain without radiographic arthritis; 49 and 47 completed | - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with Chronic Knee Pain ↗
|
|---|
| Menstrual pain | In the second cycle, pain was on average 0.8 points out of 10 lower with the extract–phosphatidylcholine complex than with placebo; both groups could use the ibuprofen provided.in the second cycle, adjusted difference −0.8 points (95% CI −1.4…−0.1), p=0.012 | 1/4 Very lowPrecision of the estimate: 62 women, CI allows a small change. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Comparison of an extract–phosphatidylcholine complex; not transferable to an individual component. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple time points and scales, ibuprofen consumption not fully measured. | 11 randomised trialThe effect of oral curcumin capsules on symptoms of premenstrual syndrome and dysmenorrhea: a randomized controlled trial ↗ | 62 female students aged 18–25 with PMS and primary dysmenorrhoea, 31 versus 31 | - The effect of oral curcumin capsules on symptoms of premenstrual syndrome and dysmenorrhea: a randomized controlled trial ↗
|
|---|
| Premenstrual syndrome symptoms | In the second cycle, the overall PMS symptom score was lower with the extract–phosphatidylcholine complex than with placebo.in the second cycle, adjusted difference −5.2 points (95% CI −9.6…−0.9), p=0.018 | 1/4 Very lowPrecision of the estimate: 62 women, CI allows a small change. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Comparison of an extract–phosphatidylcholine complex; not transferable to an individual component. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Multiple time points and scales, ibuprofen consumption not fully measured. | 11 randomised trialThe effect of oral curcumin capsules on symptoms of premenstrual syndrome and dysmenorrhea: a randomized controlled trial ↗ | 62 female students aged 18–25 with PMS and primary dysmenorrhoea, 31 versus 31 | - The effect of oral curcumin capsules on symptoms of premenstrual syndrome and dysmenorrhea: a randomized controlled trial ↗
|
|---|
| Overall functional dyspepsia symptoms | A review of two trials reported a reduction in the overall functional dyspepsia symptom score with the products studied compared with placebo over four weeks.MD −3.33 (95% CI −5.84…−0.81), I² 47% | 3/4 ModeratePrecision of the estimate: Enough data for a limited conclusion. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Two small trials and limited reproducibility. | 22 randomised trialsNon-Chinese herbal medicines for functional dyspepsia ↗ | 110 adults with functional dyspepsia in 2 RCTs | - Non-Chinese herbal medicines for functional dyspepsia ↗
|
|---|
| Sleep quality in diabetic retinopathy | In patients with non-proliferative diabetic retinopathy, the curcumin–piperine combination slightly improved the PSQI sleep score compared with placebo over 12 weeks.change −0.91±1.28 versus −0.34±0.95, p=0.025 | 1/4 Very lowPrecision of the estimate: 56 completed, exact CI of the effect not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Combination with piperine in patients with retinopathy. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Inconsistent reporting of sex, several outcomes. | 11 randomised trialThe Effect of Curcumin Plus Piperine on Mental Health Status, Sleep Quality, and Anthropometric Indices in Patients with Non-Proliferative Diabetic Retinopathy: A Randomized Double-Blind Placebo-Controlled Trial. ↗ | 60 patients with non-proliferative diabetic retinopathy randomised; 56 completed | - The Effect of Curcumin Plus Piperine on Mental Health Status, Sleep Quality, and Anthropometric Indices in Patients with Non-Proliferative Diabetic Retinopathy: A Randomized Double-Blind Placebo-Controlled Trial. ↗
|
|---|
| Systolic blood pressure in prediabetes or T2DM | In the review, adults with prediabetes or T2DM had systolic blood pressure on average 2.69 mmHg lower with the products studied than with control.MD −2.69 mmHg (95% CI −3.84…−1.55), I² 30.1% | 1/4 Very lowPrecision of the estimate: The interval allows a small effect or no effect. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Different forms, some mixtures; patients with dysglycaemia were studied. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Limited quality of individual RCTs. | 11 systematic review; the number of trials for this specific outcome was not separately establishedAntihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials ↗ | 855 adults with prediabetes or type 2 diabetes, 15 RCTs | - Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials ↗
|
|---|
| Diastolic blood pressure in prediabetes or T2DM | The review found no convincing difference in diastolic blood pressure between the products studied and control.MD −1.20 mmHg (95% CI −2.84…+0.44), I² 84.3% | 1/4 Very lowPrecision of the estimate: The interval allows a small effect or no effect. Consistency of results: I²=84.3%. Applicability to the stated group: Different forms, some mixtures; patients with dysglycaemia were studied. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Limited quality of individual RCTs. | 11 systematic review; the number of trials for this specific outcome was not separately establishedAntihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials ↗ | 855 adults with prediabetes or type 2 diabetes, 15 RCTs | - Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials ↗
|
|---|
| Body weight in T2DM | In the subgroup of adults with T2DM, body weight was on average 1.9 kg lower with the products studied than with control.−1.9 kg (95% CI −2.9…−0.9); authors' certainty low | 1/4 Very lowPrecision of the estimate: Uncertain transferability of the magnitude to an individual product. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Different forms and the T2DM clinical group. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small, differing trials. | 11 systematic review; the number of trials for this specific outcome was not separately establishedThe effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗ | adults with type 2 diabetes in a subgroup of the review of 20 RCTs/1387 total participants | - The effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗
|
|---|
| Waist circumference in T2DM | In the subgroup of adults with T2DM, waist circumference was on average 1.9 cm smaller with the products studied than with control.−1.9 cm (95% CI −3.5…−0.2), I² 96.1% | 1/4 Very lowPrecision of the estimate: Uncertain transferability of the magnitude to an individual product. Consistency of results: Very high heterogeneity. Applicability to the stated group: Different forms and the T2DM clinical group. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small, differing trials. | 11 systematic review; the number of trials for this specific outcome was not separately establishedThe effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗ | adults with type 2 diabetes in a subgroup of the review of 20 RCTs/1387 total participants | - The effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗
|
|---|
| Body mass index in T2DM | In the subgroup of adults with T2DM, no convincing difference in body mass index between the products studied and control was found.−0.52 kg/m² (95% CI −1.27…+0.23), I² 99.2% | 1/4 Very lowPrecision of the estimate: Uncertain transferability of the magnitude to an individual product. Consistency of results: Very high heterogeneity. Applicability to the stated group: Different forms and the T2DM clinical group. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small, differing trials. | 11 systematic review; the number of trials for this specific outcome was not separately establishedThe effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗ | adults with type 2 diabetes in a subgroup of the review of 20 RCTs/1387 total participants | - The effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗
|
|---|
| Body weight in prediabetes | In the subgroup of adults with prediabetes, body weight was on average 2.5 kg lower with the products studied than with control.MD −2.5 kg (95% CI −4.8…−0.2). | 1/4 Very lowPrecision of the estimate: The interval is close to zero. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Different formulations; prediabetes only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Limitations of the primary RCTs. | 11 systematic review; the number of trials for this specific outcome was not separately establishedThe effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗ | Adults with prediabetes in a subgroup of the review of 20 RCTs/1387 total participants | - The effect of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. ↗
|
|---|
| Everyday knee function in osteoarthritis | In knee osteoarthritis, the KOOS ADL everyday function score improved more with WDTE60N than with placebo over 90 days.change +16.85 (95% CI of group 15.42–18.27) versus +7.82 (6.12–9.52); p<0.0001 for the difference in changes | 1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis. | 11 randomised trialEfficacy and Safety of a Novel Low-Dose Water-Dispersible Turmeric Extract in the Management of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗ | 140 randomised adults with knee osteoarthritis, 70 and 69 completed | - Efficacy and Safety of a Novel Low-Dose Water-Dispersible Turmeric Extract in the Management of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial ↗
|
|---|
| Time to walk 80 metres in chronic knee pain | Time to walk 80 metres briskly decreased more with WDTE60N than with placebo according to the authors; the table has an unusual relationship between means and medians.changes −11.0±26.1 versus −6.8±23.3 s, p=0.0011 according to the article; distributions and the table have an unusual relationship between means and medians | 1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis. | 11 randomised trialA Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with Chronic Knee Pain ↗ | 106 adults with chronic knee pain without radiographic arthritis, 49 and 47 completed | - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Assessing Efficacy and Safety of a Novel Low-Dose Turmeric Extract Formulation in Healthy Adults with Chronic Knee Pain ↗
|
|---|
| Depressive symptoms in different adult groups | The review reported fewer depressive symptoms than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.SMD −1.53 (95% CI −2.05…−1.02), I² 94.8% | 1/4 Very lowPrecision of the estimate: Uncertain effect size in a specific group. Consistency of results: I² approximately 95% or higher. Applicability to the stated group: Heterogeneous clinical populations and products. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Authors' GRADE described differently across sections, RCT limitations. | 11 systematic review; the number of trials for this specific outcome was not separately establishedEffects of curcumin on depression, anxiety, and stress symptoms in adults: a GRADE-assessed systematic review and dose–response meta-analysis ↗ | Different adult populations, including patients taking antidepressants; 1491 participants/26 RCTs concern the whole review, not just this outcome. | - Effects of curcumin on depression, anxiety, and stress symptoms in adults: a GRADE-assessed systematic review and dose–response meta-analysis ↗
|
|---|
| Anxiety symptoms in different adult groups | The review reported fewer anxiety symptoms than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.SMD −1.67 (95% CI −2.42…−0.93), I² 95.7% | 1/4 Very lowPrecision of the estimate: Uncertain effect size in a specific group. Consistency of results: I² approximately 95% or higher. Applicability to the stated group: Heterogeneous clinical populations and products. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Authors' GRADE described differently across sections, RCT limitations. | 11 systematic review; the number of trials for this specific outcome was not separately establishedEffects of curcumin on depression, anxiety, and stress symptoms in adults: a GRADE-assessed systematic review and dose–response meta-analysis ↗ | Different adult populations, including patients taking antidepressants; 1491 participants/26 RCTs concern the whole review, not just this outcome. | - Effects of curcumin on depression, anxiety, and stress symptoms in adults: a GRADE-assessed systematic review and dose–response meta-analysis ↗
|
|---|
| Stress symptoms in different adult groups | The review reported lower stress scores than with placebo in mixed adult groups; marked heterogeneity prevents predicting the benefit size for an individual.SMD −1.71 (95% CI −3.37…−0.06), I² 96.3% | 1/4 Very lowPrecision of the estimate: Uncertain effect size in a specific group. Consistency of results: I² approximately 95% or higher. Applicability to the stated group: Heterogeneous clinical populations and products. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Authors' GRADE described differently across sections, RCT limitations. | 44 randomised trialsEffects of curcumin on depression, anxiety, and stress symptoms in adults: a GRADE-assessed systematic review and dose–response meta-analysis ↗ | Different adult populations, including patients taking antidepressants; 1491 participants/26 RCTs concern the whole review, not just this outcome. | - Effects of curcumin on depression, anxiety, and stress symptoms in adults: a GRADE-assessed systematic review and dose–response meta-analysis ↗
|
|---|
| Overall nasal symptoms: CurQfen CGM | CurQfen CGM showed no convincing advantage over placebo in the overall nasal symptom score over 28 days.7.57±1.83→6.84±1.62 versus 7.60±1.83→7.48±1.43; ANCOVA p=0.099 | 1/4 Very lowPrecision of the estimate: CI of the direct contrast not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The formulation contains a fenugreek matrix. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Three groups, several outcomes and a sponsor's product. | 11 randomised trialShort-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study ↗ | adults with mild allergic rhinitis in a three-arm RCT | - Short-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study ↗
|
|---|
| Sneezing in perennial allergic rhinitis | The primary abstract of the perennial allergic rhinitis study reports improved sneezing when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.The primary abstract reports improvement; numerical between-group effect and CI not extracted. | 1/4 Very lowPrecision of the estimate: No numerical contrast or CI. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Perennial rhinitis and the specific curcumin only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Full text and randomisation details unavailable. | 11 randomised trialEffect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗ | 241 patients with perennial allergic rhinitis | - Effect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗
|
|---|
| Runny nose in perennial allergic rhinitis | The primary abstract of the perennial allergic rhinitis study reports improved runny nose when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.The primary abstract reports improvement; numerical between-group effect and CI not extracted. | 1/4 Very lowPrecision of the estimate: No numerical contrast or CI. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Perennial rhinitis and the specific curcumin only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Full text and randomisation details unavailable. | 11 randomised trialEffect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗ | 241 patients with perennial allergic rhinitis | - Effect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗
|
|---|
| Nasal congestion in perennial allergic rhinitis | The primary abstract of the perennial allergic rhinitis study reports improved nasal congestion when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.The primary abstract reports improvement; numerical between-group effect and CI not extracted. | 1/4 Very lowPrecision of the estimate: No numerical contrast or CI. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Perennial rhinitis and the specific curcumin only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Full text and randomisation details unavailable. | 11 randomised trialEffect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗ | 241 patients with perennial allergic rhinitis | - Effect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗
|
|---|
| Nasal airflow resistance in perennial allergic rhinitis | The primary abstract of the perennial allergic rhinitis study reports improved nasal airflow resistance when comparing the curcumin studied with placebo over two months; the numerical between-group difference is not stated in the available abstract.The primary abstract reports improvement; numerical between-group effect and CI not extracted. | 1/4 Very lowPrecision of the estimate: No numerical contrast or CI. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Perennial rhinitis and the specific curcumin only. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Full text and randomisation details unavailable. | 11 randomised trialEffect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗ | 241 patients with perennial allergic rhinitis | - Effect of curcumin on nasal symptoms and airflow in patients with perennial allergic rhinitis. ↗
|
|---|
| Hot flush frequency after menopause | In postmenopausal women, the standardised mixture studied reduced hot flush frequency by about seven per week more than placebo over 12 weeks.difference in changes −7.35 hot flushes/week (95% CI −10.29…−4.41), p<0.001 | 2/4 LowPrecision of the estimate: CI allows a change of about one hot flush a day or less. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Retrospective registration, small pilot. | 11 randomised trialCurcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial ↗ | 40 postmenopausal women aged 41–65, double-blind pilot RCT | - Curcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial ↗
|
|---|
| Quality of life after menopause: MENQOL | At week 12, no advantage of the mixture studied over placebo was found for overall MENQOL quality of life.At week 12, no significant between-group difference was found. | 2/4 LowPrecision of the estimate: Small sample, exact CI of the contrast not confirmed. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Retrospectively registered pilot with several secondary outcomes. | 11 randomised trialCurcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial ↗ | The same 40 postmenopausal women aged 41–65 from the hot_flash trial. | - Curcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial ↗
|
|---|
| Overall menopause symptoms: MRS II | At week 12, no advantage of the mixture studied over placebo was found for the overall MRS II symptom score.At week 12, no significant between-group difference was found. | 2/4 LowPrecision of the estimate: Small sample, exact CI of the contrast not confirmed. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: The measurement directly answers the specific narrow PICO. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Retrospectively registered pilot with several secondary outcomes. | 11 randomised trialCurcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial ↗ | The same 40 postmenopausal women aged 41–65 from the hot_flash trial. | - Curcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial ↗
|
|---|
| Preservation of knee-extension strength after downhill running in men | In men a day after downhill running, the loss of peak knee-extension torque was smaller with the colloidal formulation studied than with placebo; this is a secondary test in one crossover trial.−9.2±4.2 versus −20.2±4.2 N·m; difference +11.0±4.9 N·m, p=0.0275; SE values | 1/4 Very lowPrecision of the estimate: The CI of the direct contrast was not extracted or concerns group means. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Exact protocol and specific formulation. Possible publication bias: There are no specific data for a separate downgrade. Study methods: Small groups, several outcomes or completer analysis. | 11 randomised trialA randomized, placebo-controlled, crossover clinical trial to evaluate the effect of a turmeric formulation on muscle soreness and function recovery in moderately active adults. ↗ | 34 men in a crossover RCT, 44 active adults in total | - A randomized, placebo-controlled, crossover clinical trial to evaluate the effect of a turmeric formulation on muscle soreness and function recovery in moderately active adults. ↗
|
|---|
| Change in body fat percentage in men at high altitude | In men at high altitude, the overall group×time analysis showed no convincing difference in body fat percentage change; individual positive tests do not establish a fat-loss advantage.In frozen QUESTION_13: overall group×time analysis not significant; p=0.030 concerns the group effect, p=0.032 the change during the altitude stage; exact CI of the effect not extracted. | 1/4 Very lowPrecision of the estimate: Exact CI of the effect not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Men at high altitude, BIA is an indirect method. Possible publication bias: There are no specific data for a separate downgrade. Study methods: 12 dropped out, several BIA measures. | 11 randomised trialCurcumin supplementation during high-altitude exposure modulates body composition and its relationship with gut microbiota: a randomized controlled trial. ↗ | 102 healthy Han Chinese men aged 18–45 randomised, 44 and 46 completed | - Curcumin supplementation during high-altitude exposure modulates body composition and its relationship with gut microbiota: a randomized controlled trial. ↗
|
|---|
| Fat-free and muscle mass in men at high altitude | In men at high altitude, total fat-free mass and muscle mass increased in both groups; no convincing advantage of curcumin over placebo was found.increase in both groups; between-group difference not statistically significant according to the authors | 1/4 Very lowPrecision of the estimate: Exact CI of the effect not extracted. Consistency of results: There are no grounds for a separate downgrade. Applicability to the stated group: Men at high altitude, BIA is an indirect method. Possible publication bias: There are no specific data for a separate downgrade. Study methods: 12 dropped out, several BIA measures. | 11 randomised trialCurcumin supplementation during high-altitude exposure modulates body composition and its relationship with gut microbiota: a randomized controlled trial. ↗ | 102 healthy Han Chinese men aged 18–45 randomised, 44 and 46 completed; the same high-altitude sample as fat_altitude. | - Curcumin supplementation during high-altitude exposure modulates body composition and its relationship with gut microbiota: a randomized controlled trial. ↗
|
|---|
| Quality of life in functional dyspepsia: EQ-5D | In adults with functional dyspepsia, the capsules studied gave a small average improvement in EQ-5D quality of life after four weeks compared with placebo.MD +0.05 EQ-5D points (95% CI +0.01…+0.09), four weeks; 89 participants. | 3/4 ModeratePrecision of the estimate: 89 participants; CI allows a very small improvement; the threshold noticeable to an individual was not tested. Consistency of results: One RCT; between-study heterogeneity cannot be assessed. Applicability to the stated group: The conclusion is limited to the exact population, capsules, duration and EQ-5D; other forms are not equated. Possible publication bias: Not established from one trial; no specific reason for a separate downgrade. Study methods: Specific secondary-source information is available on randomisation, concealment, blinding, data completeness and concordance of outcomes with the registry; no serious defect in this contrast has been established. | 11 randomised trialNon-Chinese herbal medicines for functional dyspepsia ↗ | 89 adults aged 18–80 with RomeIV functional dyspepsia in two relevant arms of one Thai RCT; 45 in the studied arm, 44 on placebo. | - Non-Chinese herbal medicines for functional dyspepsia ↗
|
|---|